These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34856892)

  • 21. Tubulin Inhibitors Binding to Colchicine-Site: A Review from 2015 to 2019.
    Xia LY; Zhang YL; Yang R; Wang ZC; Lu YD; Wang BZ; Zhu HL
    Curr Med Chem; 2020; 27(40):6787-6814. PubMed ID: 31580244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
    Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents.
    Hu Y; Lu X; Chen K; Yan R; Li QS; Zhu HL
    Bioorg Med Chem; 2012 Jan; 20(2):903-9. PubMed ID: 22192936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of Combretastatin-A4 Carboxamidest that Mimic Sulfonyl Piperazines by a Molecular Hybridization Approach: in vitro Cytotoxicity Evaluation and Inhibition of Tubulin Polymerization.
    Jadala C; Sathish M; Anchi P; Tokala R; Lakshmi UJ; Reddy VG; Shankaraiah N; Godugu C; Kamal A
    ChemMedChem; 2019 Dec; 14(24):2052-2060. PubMed ID: 31674147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents.
    Romagnoli R; Oliva P; Salvador MK; Manfredini S; Padroni C; Brancale A; Ferla S; Hamel E; Ronca R; Maccarinelli F; Rruga F; Mariotto E; Viola G; Bortolozzi R
    Eur J Med Chem; 2021 Mar; 214():113229. PubMed ID: 33550186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 2-step synthesis of Combretastatin A-4 and derivatives as potent tubulin assembly inhibitors.
    Barnes NG; Parker AW; Ahmed Mal Ullah AA; Ragazzon PA; Hadfield JA
    Bioorg Med Chem; 2020 Oct; 28(19):115684. PubMed ID: 32912434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers.
    Rajak H; Dewangan PK; Patel V; Jain DK; Singh A; Veerasamy R; Sharma PC; Dixit A
    Curr Pharm Des; 2013; 19(10):1923-55. PubMed ID: 23237054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent combretastatin A-4 analogs containing 1,2,4-triazole: Synthesis, antiproliferative, anti-tubulin activity, and docking study.
    Mustafa M; Anwar S; Elgamal F; Ahmed ER; Aly OM
    Eur J Med Chem; 2019 Dec; 183():111697. PubMed ID: 31536891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function.
    Schmitt F; Gosch LC; Dittmer A; Rothemund M; Mueller T; Schobert R; Biersack B; Volkamer A; Höpfner M
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological studies of novel tubulin inhibitors.
    Sun Y; Pandit B; Chettiar SN; Etter JP; Lewis A; Johnsamuel J; Li PK
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4465-8. PubMed ID: 23790539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition.
    Romagnoli R; Kimatrai Salvador M; Schiaffino Ortega S; Baraldi PG; Oliva P; Baraldi S; Lopez-Cara LC; Brancale A; Ferla S; Hamel E; Balzarini J; Liekens S; Mattiuzzo E; Basso G; Viola G
    Eur J Med Chem; 2018 Jan; 143():683-698. PubMed ID: 29220790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.
    Penthala NR; Zong H; Ketkar A; Madadi NR; Janganati V; Eoff RL; Guzman ML; Crooks PA
    Eur J Med Chem; 2015 Mar; 92():212-20. PubMed ID: 25557492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors.
    González M; Ellahioui Y; Álvarez R; Gallego-Yerga L; Caballero E; Vicente-Blázquez A; Ramudo L; Marín M; Sanz C; Medarde M; Pelaéz R
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.
    Ducki S; Mackenzie G; Greedy B; Armitage S; Chabert JF; Bennett E; Nettles J; Snyder JP; Lawrence NJ
    Bioorg Med Chem; 2009 Nov; 17(22):7711-22. PubMed ID: 19837594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy.
    Hawash M
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents.
    Duan YT; Man RJ; Tang DJ; Yao YF; Tao XX; Yu C; Liang XY; Makawana JA; Zou MJ; Wang ZC; Zhu HL
    Sci Rep; 2016 May; 6():25387. PubMed ID: 27138035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.
    McGown AT; Fox BW
    Anticancer Drug Des; 1989 Mar; 3(4):249-54. PubMed ID: 2930627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of new trimethoxylphenyl-linked combretastatin analogues loaded on diamond nanoparticles as a panel for ameliorated solubility and antiproliferative activity.
    Zaki I; Moustafa AMY; Beshay BY; Masoud RE; Elbastawesy MAI; Abourehab MAS; Zakaria MY
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2679-2701. PubMed ID: 36154552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclic bridged analogs of isoCA-4: Design, synthesis and biological evaluation.
    Pecnard S; Provot O; Levaique H; Bignon J; Askenatzis L; Saller F; Borgel D; Michallet S; Laisne MC; Lafanechère L; Alami M; Hamze A
    Eur J Med Chem; 2021 Jan; 209():112873. PubMed ID: 33038796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.